TABLE OF CONTENTS FOR ASIA PACIFIC STEM CELL THERAPY MARKET REPORT

1. INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

3. EXECUTIVE SUMMARY

• 3.1 Market Highlights

4. VOICE OF CUSTOMER

• 4.1 Product and Market Intelligence
• 4.2 Factors Considered in Purchase Decisions
  • 4.2.1. Features
  • 4.2.2. Compatibility
  • 4.2.3. Durability
  • 4.2.4. Efficiency of Solutions
  • 4.2.4. After-Sales Support
  • 4.2.5. Consideration of Regulations

5. MARKET DYNAMICS

• 5.1. MARKET OVERVIEW
• 5.2. Demand Supply Analysis
• 5.3. Import and Export Analysis
• 5.4. Value Chain Analysis
• 5.5. Porter’s Five Forces Analysis
• 5.6. PESTLE Analysis
• 5.7. Pricing Analysis
• 5.8. MARKET DYNAMICS
• 5.9 Market Drivers
  • 5.9.1 Growing synergy between advanced cell technologies and personalized medicine strategies is accelerating Asia Pacific developments.
• 5.10 MARKET RESTRAINTS
  • 5.10.1 Bottlenecks in scaling production processes and ensuring consistent quality hamper emerging stem cell initiatives
• 5.11 MARKET OPPORTUNITY
  • 5.11.1 Heightened utilization of artificial intelligence optimizing personalized cell therapy outcomes
• 5.12 PORTER'S FIVE FORCE ANALYSIS
  • 5.12.1 Bargaining Power of Buyers/Consumers
  • 5.12.2 Bargaining Power of Suppliers
  • 5.12.3 Threat of New Entrants
  • 5.12.4 Threat of Substitute Products
  • 5.12.5 Intensity of Competitive Rivalry

6. MARKET SIZE AND GROWTH FORECASTS (VALUE)

• 6.1 By Therapy Type
  • 6.1.1 Autologous Stem Cell Therapy
  • 6.1.2. Allogeneic Stem Cell Therapy
• 6.2 By Product
  • 6.2.1 Adult Stem Cells (ASCs)
  • 6.2.2. Human Embryonic Stem Cells (HESCs)
  • 6.2.3. Induced Pluripotent Stem Cells (iPSCs)
  • 6.2.4. Very Small Embryonic Like Stem Cells
• 6.3 By Cell Source
  • 6.3.1 Adipose tissue derived MSCs
  • 6.3.2. Bone marrow derived MSCs
  • 6.3.3. Placental/umbilical cord derived MSCs
  • 6.3.4. Other Cell Sources
• 6.4 By Technology
  • 6.4.1 Cell Acquisition
  • 6.4.2. Cell Production
  • 6.4.3. Cryopreservation
  • 6.4.4. Expansion and Sub-Culture
• 6.5 By Application 
  • 6.5.1 Musculoskeletal Disorders
  • 6.5.2. Wounds and Injuries
  • 6.5.3 Acute Graft-Versus-Host Disease (AGVHD)
  • 6.5.4. Surgeries
  • 6.5.5. Gastrointestinal Diseases
  • 6.5.6. Cardiovascular Diseases
  • 6.5.7. Inflammatory & Autoimmune Diseases
  • 6.5.8. Neurological Disorders
  • 6.5.9. Others
• 6.6 By End User
  • 6.6.1 Hospitals
  • 6.6.2. Research institutes
  • 6.6.3. Surgical institutes
  • 6.6.4. Others
• 6.7 By Geography
  • 6.7.1 China
  • 6.7.2 India
  • 6.7.3 Japan
  • 6.7.4 South Korea
  • 6.7.5 Australia and New Zealand
  • 6.7.6 Indonesia
  • 6.7.7 Thailand
  • 6.7.8 Malaysia
  • 6.7.9 Vietnam
  • 6.7.10 Philippines
  • 6.7.11 Singapore
  • 6.7.12 Rest of Asia-Pacific

7. COMPETITIVE LANDSCAPE

• 7.1 Market Concentration
• 7.2 Strategic Moves
• 7.3 Market Share (%)/Ranking Analysis
• 7.4 Company Profiles
  • 7.4.1 AlloSource
  • 7.4.2 Anterogen Co., Ltd.
  • 7.4.3 Arce Therapeutics
  • 7.4.4 Astellas Pharma Inc
  • 7.4.5 Biogend Therapeutics
  • 7.4.6 Biorestorative Therapies Inc.
  • 7.4.7. Brainstorm Cell Limited.
  • 7.4.8. Cellular Biomedicine Group
  • 7.4.9. CORESTEM
  • 7.4.10 Fujifilm Holding Corporation
  • 7.4.11. Holostem Terapie Avanzate Srl
  • 7.4.12. JCR Pharmaceuticals Co., Ltd.
  • 7.4.13. Kangstem Biotech
  • 7.4.14. MEDIPOST Co., Ltd.
  • 7.4.15. Mesoblast Ltd .
  • 7.4.16. Personalized Stem Cells
  • 7.4.17. PELL Biotech Co., Ltd.
  • 7.4.18. Pluristem Inc.
  • 7.4.19 RTI Surgical
  • 7.4.20 Sartorius AG
  • 7.4.21. Sewon Cellontech
  • 7.4.22. Smith+Nephew
  • 7.4.23. STEMPEUTICS RESEARCH PVT LTD.
  • 7.4.24. Takeda Pharmaceutical Company Limited
  • 7.4.25. Vericel Corp
  • 7.4.26. Others 

8. MARKET OPPORTUNITIES AND FUTURE OUTLOOK

• 8.1 White-space and Unmet-need Assessment